Vaxart (VXRT) Competitors $0.45 +0.10 (+29.05%) As of 07/11/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VXRT vs. IVA, GOSS, OCGN, RNAC, NGNE, PVLA, ADCT, TKNO, FHTX, and SGMTShould you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include Inventiva (IVA), Gossamer Bio (GOSS), Ocugen (OCGN), Cartesian Therapeutics (RNAC), Neurogene (NGNE), Palvella Therapeutics (PVLA), ADC Therapeutics (ADCT), Alpha Teknova (TKNO), Foghorn Therapeutics (FHTX), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry. Vaxart vs. Its Competitors Inventiva Gossamer Bio Ocugen Cartesian Therapeutics Neurogene Palvella Therapeutics ADC Therapeutics Alpha Teknova Foghorn Therapeutics Sagimet Biosciences Vaxart (NASDAQ:VXRT) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability. Which has more volatility and risk, VXRT or IVA? Vaxart has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Do analysts rate VXRT or IVA? Vaxart presently has a consensus target price of $3.00, suggesting a potential upside of 569.94%. Inventiva has a consensus target price of $10.40, suggesting a potential upside of 210.45%. Given Vaxart's stronger consensus rating and higher possible upside, equities research analysts clearly believe Vaxart is more favorable than Inventiva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxart 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do insiders and institutionals have more ownership in VXRT or IVA? 18.0% of Vaxart shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 2.9% of Vaxart shares are held by company insiders. Comparatively, 32.0% of Inventiva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor VXRT or IVA? In the previous week, Inventiva had 3 more articles in the media than Vaxart. MarketBeat recorded 7 mentions for Inventiva and 4 mentions for Vaxart. Vaxart's average media sentiment score of 1.41 beat Inventiva's score of 0.28 indicating that Vaxart is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxart 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, VXRT or IVA? Vaxart has higher revenue and earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxart$47.40M2.16-$66.95M-$0.27-1.66Inventiva$9.95M32.21-$199.34MN/AN/A Is VXRT or IVA more profitable? Inventiva has a net margin of 0.00% compared to Vaxart's net margin of -122.63%. Inventiva's return on equity of 0.00% beat Vaxart's return on equity.Company Net Margins Return on Equity Return on Assets Vaxart-122.63% -91.89% -38.40% Inventiva N/A N/A N/A SummaryInventiva beats Vaxart on 8 of the 14 factors compared between the two stocks. Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VXRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VXRT vs. The Competition Export to ExcelMetricVaxartMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.24M$2.74B$5.62B$9.10BDividend YieldN/A1.79%5.24%4.00%P/E Ratio-1.669.4228.1320.27Price / Sales2.16714.13428.6398.72Price / CashN/A165.3637.4658.16Price / Book1.724.608.045.49Net Income-$66.95M$31.26M$3.18B$250.45M7 Day Performance3.66%4.80%3.62%4.78%1 Month Performance-16.61%5.42%4.05%7.67%1 Year Performance-33.19%-4.36%30.00%16.43% Vaxart Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VXRTVaxart3.5527 of 5 stars$0.45+29.0%$3.00+569.9%-33.6%$102.24M$47.40M-1.66120News CoveragePositive NewsGap DownIVAInventiva3.2067 of 5 stars$3.02+0.3%$10.40+244.4%+22.9%$288.90M$9.20M0.00100News CoverageGOSSGossamer Bio3.8377 of 5 stars$1.25+0.8%$7.33+486.7%+10.6%$284.13M$114.70M-5.43180OCGNOcugen1.5186 of 5 stars$0.97+1.4%$6.00+518.6%-38.0%$283.27M$4.05M-5.1180RNACCartesian Therapeutics2.2661 of 5 stars$10.77-3.9%$40.67+277.6%-25.0%$279.48M$38.91M-0.2064News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGap DownNGNENeurogene3.3111 of 5 stars$19.50-2.9%$46.17+136.8%-48.7%$278.07M$930K-4.4890Gap UpPVLAPalvella Therapeutics2.5034 of 5 stars$24.90+3.2%$46.29+85.9%N/A$275.39M$42.81M-2.06N/AADCTADC Therapeutics1.279 of 5 stars$2.70-5.3%$7.75+187.0%-16.5%$267.78M$75.82M-1.86310News CoverageGap DownTKNOAlpha Teknova2.2482 of 5 stars$4.99-4.2%$8.50+70.3%+287.9%$266.67M$37.74M-10.40240Positive NewsFHTXFoghorn Therapeutics1.9611 of 5 stars$4.78-6.8%$12.13+153.7%-8.0%$266.44M$23.50M-3.51120Positive NewsGap DownSGMTSagimet Biosciences3.0045 of 5 stars$8.68+5.2%$26.60+206.5%+189.6%$266.22M$2M-4.938 Related Companies and Tools Related Companies Inventiva Competitors Gossamer Bio Competitors Ocugen Competitors Cartesian Therapeutics Competitors Neurogene Competitors Palvella Therapeutics Competitors ADC Therapeutics Competitors Alpha Teknova Competitors Foghorn Therapeutics Competitors Sagimet Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VXRT) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
